Key facts, as of
As of October 11, 2026, Johnson & Johnson (JNJ) trades at $261.44, up 36.8% over the past year. Its 52-week range runs from $184.66 to $281.07; the price is 7.0% below that high. It is 7.0% below its all-time high of $281.07, reached in September 2026. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +194.1%, against +312.9% for the S&P 500 (SPY). It sits 7.6% above its 200-day average of $242.92, the usual sign of a long-term uptrend. Its 30-day volatility is 15.6% annualized, which we rate medium risk. It has a trailing P/E of 30.3 and a dividend yield of 2.05%.
Cite: Portfolio Terminal, "Johnson & Johnson (JNJ) stock analysis", 2026-10-11. https://portfolio-terminal.com/analyse/jnj
Where it trades today
trading 80% of the way up its 52-week range
How the price has moved
How far it is from its record
Johnson & Johnson (JNJ) is 7.0% below its all-time high of $281.07, reached in September 2026. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +194.1%, against +312.9% for the S&P 500 (SPY).
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- JNJ trades at 30.3x earnings, well above the healthcare average of 22.0x, so the market is already pricing in above-consensus execution.
- Recent realized volatility sits near 15.6%, below the sector norm of 22.0%, which supports a steadier role inside a diversified portfolio.
- Relative performance versus UNH, PFE, ABBV matters here because leadership inside healthcare rarely stays static for long.
Portfolio Use Case
- JNJ is more relevant for investors who want some income support alongside price appreciation, not just pure growth exposure.
- The beta profile suggests it can fit a quality or lower-volatility sleeve more naturally than a high-octane tactical basket.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A reset in earnings expectations or a faster peer catch-up could compress the premium valuation currently embedded in JNJ.
- The view would need revisiting if peers such as UNH, PFE, ABBV start winning the marginal flow or posting cleaner operating momentum.
Methodology
- Price, market cap, beta, yield, and liquidity fields for JNJ come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, PFE, ABBV.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for JNJ. Last refresh: Oct 11, 2026, 11:16 PM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, PFE, ABBV.
What Johnson & Johnson does
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through…
Employees
138,200
Industry
Drug Manufacturers - General
Headquarters
New Brunswick, United States
What analysts expect
JNJ carries a buy consensus from 22 analysts, with an average price target of $279.82 versus $261.44 today (+7.0%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
JNJ generated $97.93B in trailing revenue (6.6% year over year), with a 21.5% net margin, and $16.89B of free cash flow, against $28.28B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $94.19B | $63.94B | $25.60B | $26.80B | $11.13 | $19.31B |
| 2024 | $88.82B | $61.35B | $21.25B | $14.07B | $5.84 | $18.06B |
| 2023 | $85.16B | $58.61B | $22.01B | $35.15B | $14.60 | $17.78B |
| 2022 | $79.99B | $55.39B | $21.01B | $17.94B | $6.86 | $17.18B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
JNJ is in 10 of the 30 ETFs we track. It weighs most in XLV: 10.6% of the fund, holding #2 of 62.
Famous investors who hold it
JNJ is in the latest 13F of 2 of the 15 famous investors we follow. Ray Dalio (Bridgewater Associates) holds the most of it: 0.70% of the portfolio, position #17 of 992, as of Q2 2026.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
JNJ beside the healthcare names it is usually measured against.
What the chart is saying
Slipped under its 50-day average inside a longer uptrend.
weakening- Price is 1.5% below its 50-day average and 7.6% above its 200-day.
- RSI at 47 is neither stretched nor washed out.
- The nearest ceiling is $275.53 (+5.4%), the nearest floor $251.08 (-4.0%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
Is JNJ a good investment in 2026?
Johnson & Johnson trades at a P/E ratio of 30.3, with medium volatility (15.6% annualized). The stock is in a consolidation phase.
What is the risk level of JNJ?
Based on 30-day volatility of 15.6%, JNJ has MEDIUM risk. Beta of 0.21 indicates lower sensitivity to market movements than average.
Does JNJ pay dividends?
Yes, Johnson & Johnson has a dividend yield of 2.05%.
How far is JNJ from its all-time high?
Johnson & Johnson is 7.0% below its all-time high of $281.07, reached in September 2026. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +194.1%, against +312.9% for the S&P 500 (SPY).
Which ETFs hold JNJ?
10 of the 30 popular ETFs we track hold Johnson & Johnson. The largest weights: XLV (10.6%), DIA (3.13%), VIG (2.73%), VYM (2.57%) and VTV (2.33%). Measured on each issuer's full holdings file, dated August 31 to September 24, 2026.
How much of VOO is JNJ?
0.97%, as of August 31, 2026: JNJ is holding #16 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $9.67 in Johnson & Johnson.
Which famous investors own JNJ?
Ray Dalio (0.70% of Bridgewater Associates's 13F) and George Soros (0.11% of Soros Fund Management's 13F), according to their latest Form 13F filings with the SEC (Q2 2026). A 13F lists US long positions 45 days after the quarter ends, so it can be out of date.
What is the analyst price target for JNJ?
The average analyst price target for Johnson & Johnson (JNJ) is $279.82 based on 22 analyst estimates, about 7.0% above the current price of $261.44. The published range runs from $190.00 to $320.00.
How much revenue does JNJ generate?
Johnson & Johnson reported $97.93B in trailing twelve-month revenue. Revenue growth is running at 6.6% year over year. Net margin sits at 21.5%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare JNJ with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.